, Question 1
A patient with heart failure is prescribed sacubitril/valsartan. Which statement
best explains the pharmacological advantage of this combination over an ACE
inhibitor alone?
A. Sacubitril inhibits neprilysin, increasing natriuretic peptides, while
valsartan blocks angiotensin II receptors, providing dual cardioprotection.
B. Sacubitril enhances bradykinin degradation, reducing cough, while
valsartan increases angiotensin II for vasoconstriction.
C. Valsartan inhibits neprilysin, and sacubitril blocks angiotensin
receptors, leading to reduced afterload and preload.
D. The combination increases angiotensin II production, which improves
renal perfusion and reduces mortality.
Correct Answer: A - Sacubitril inhibits neprilysin, increasing
natriuretic peptides, while valsartan blocks angiotensin II
receptors, providing dual cardioprotection.
RATIONALE
Sacubitril inhibits neprilysin, which degrades natriuretic peptides,
thereby increasing their levels and promoting vasodilation and
natriuresis. Valsartan blocks angiotensin II receptors, reducing
vasoconstriction and aldosterone release. This dual mechanism
provides superior cardiovascular benefits compared to ACE inhibitors
alone. Options B, C, and D incorrectly describe the mechanisms or
effects.
Question 2
In a randomized controlled trial, the number needed to treat (NNT) is 5 for a
new drug preventing stroke over 2 years. Which interpretation is most
accurate?
A. Five patients must be treated for 2 years to prevent one additional
stroke compared to control.
B. Five percent of patients treated will experience a stroke despite
Page 2
, treatment.
C. The drug reduces stroke risk by 5% compared to placebo.
D. Five patients will experience adverse effects for every one stroke
prevented.
Correct Answer: A - Five patients must be treated for 2 years to
prevent one additional stroke compared to control.
RATIONALE
NNT represents the number of patients who need to be treated for one
additional patient to benefit (e.g., avoid a stroke) compared to control
over a specified time. It is the reciprocal of the absolute risk reduction.
Options B, C, and D misinterpret NNT as a percentage, relative risk
reduction, or harm metric.
Question 3
Which physiological change best explains why older adults are more
susceptible to hyperkalemia when prescribed spironolactone?
A. Age-related decline in renal blood flow and glomerular filtration rate
reduces potassium excretion.
B. Decreased aldosterone secretion in older adults leads to sodium
retention and potassium loss.
C. Increased renin-angiotensin system activity causes potassium
reabsorption in the distal tubule.
D. Reduced gastric motility enhances potassium absorption from the
gastrointestinal tract.
Correct Answer: A - Age-related decline in renal blood flow and
glomerular filtration rate reduces potassium excretion.
Page 3
, RATIONALE
Spironolactone is a potassium-sparing diuretic that antagonizes
aldosterone, reducing potassium excretion. Older adults often have
reduced renal function, which further impairs potassium excretion,
increasing hyperkalemia risk. Options B, C, and D incorrectly describe
aldosterone effects, RAS activity, or GI absorption as the primary
mechanism.
Question 4
A nurse practitioner is evaluating a patient with suspected Cushing's syndrome.
Which diagnostic finding would best differentiate Cushing's disease from
ectopic ACTH secretion?
A. High-dose dexamethasone suppression test showing suppression of
cortisol.
B. Low-dose dexamethasone suppression test showing no suppression.
C. Elevated 24-hour urinary free cortisol with normal ACTH levels.
D. Suppressed CRH levels with elevated ACTH.
Correct Answer: A - High-dose dexamethasone suppression test
showing suppression of cortisol.
RATIONALE
In Cushing's disease (pituitary adenoma), high-dose dexamethasone
typically suppresses cortisol due to negative feedback, whereas
ectopic ACTH secretion often does not suppress. Low-dose
dexamethasone does not differentiate the two. Elevated urinary free
cortisol and ACTH levels are seen in both. Thus, A is the key
differentiator.
Question 5
Which study design is most appropriate to determine the incidence of a rare
adverse effect of a newly approved medication in a large population over 5
years?
Page 4
A patient with heart failure is prescribed sacubitril/valsartan. Which statement
best explains the pharmacological advantage of this combination over an ACE
inhibitor alone?
A. Sacubitril inhibits neprilysin, increasing natriuretic peptides, while
valsartan blocks angiotensin II receptors, providing dual cardioprotection.
B. Sacubitril enhances bradykinin degradation, reducing cough, while
valsartan increases angiotensin II for vasoconstriction.
C. Valsartan inhibits neprilysin, and sacubitril blocks angiotensin
receptors, leading to reduced afterload and preload.
D. The combination increases angiotensin II production, which improves
renal perfusion and reduces mortality.
Correct Answer: A - Sacubitril inhibits neprilysin, increasing
natriuretic peptides, while valsartan blocks angiotensin II
receptors, providing dual cardioprotection.
RATIONALE
Sacubitril inhibits neprilysin, which degrades natriuretic peptides,
thereby increasing their levels and promoting vasodilation and
natriuresis. Valsartan blocks angiotensin II receptors, reducing
vasoconstriction and aldosterone release. This dual mechanism
provides superior cardiovascular benefits compared to ACE inhibitors
alone. Options B, C, and D incorrectly describe the mechanisms or
effects.
Question 2
In a randomized controlled trial, the number needed to treat (NNT) is 5 for a
new drug preventing stroke over 2 years. Which interpretation is most
accurate?
A. Five patients must be treated for 2 years to prevent one additional
stroke compared to control.
B. Five percent of patients treated will experience a stroke despite
Page 2
, treatment.
C. The drug reduces stroke risk by 5% compared to placebo.
D. Five patients will experience adverse effects for every one stroke
prevented.
Correct Answer: A - Five patients must be treated for 2 years to
prevent one additional stroke compared to control.
RATIONALE
NNT represents the number of patients who need to be treated for one
additional patient to benefit (e.g., avoid a stroke) compared to control
over a specified time. It is the reciprocal of the absolute risk reduction.
Options B, C, and D misinterpret NNT as a percentage, relative risk
reduction, or harm metric.
Question 3
Which physiological change best explains why older adults are more
susceptible to hyperkalemia when prescribed spironolactone?
A. Age-related decline in renal blood flow and glomerular filtration rate
reduces potassium excretion.
B. Decreased aldosterone secretion in older adults leads to sodium
retention and potassium loss.
C. Increased renin-angiotensin system activity causes potassium
reabsorption in the distal tubule.
D. Reduced gastric motility enhances potassium absorption from the
gastrointestinal tract.
Correct Answer: A - Age-related decline in renal blood flow and
glomerular filtration rate reduces potassium excretion.
Page 3
, RATIONALE
Spironolactone is a potassium-sparing diuretic that antagonizes
aldosterone, reducing potassium excretion. Older adults often have
reduced renal function, which further impairs potassium excretion,
increasing hyperkalemia risk. Options B, C, and D incorrectly describe
aldosterone effects, RAS activity, or GI absorption as the primary
mechanism.
Question 4
A nurse practitioner is evaluating a patient with suspected Cushing's syndrome.
Which diagnostic finding would best differentiate Cushing's disease from
ectopic ACTH secretion?
A. High-dose dexamethasone suppression test showing suppression of
cortisol.
B. Low-dose dexamethasone suppression test showing no suppression.
C. Elevated 24-hour urinary free cortisol with normal ACTH levels.
D. Suppressed CRH levels with elevated ACTH.
Correct Answer: A - High-dose dexamethasone suppression test
showing suppression of cortisol.
RATIONALE
In Cushing's disease (pituitary adenoma), high-dose dexamethasone
typically suppresses cortisol due to negative feedback, whereas
ectopic ACTH secretion often does not suppress. Low-dose
dexamethasone does not differentiate the two. Elevated urinary free
cortisol and ACTH levels are seen in both. Thus, A is the key
differentiator.
Question 5
Which study design is most appropriate to determine the incidence of a rare
adverse effect of a newly approved medication in a large population over 5
years?
Page 4
